Effectiveness of MenB-4C vaccine against gonorrhea: a systematic review and meta-analysis.
| Autor: | Abara WE; Division of STD Prevention, U.S Centers for Disease control and Prevention, Atlanta, Georgia 30333 United States of America., Kirkcaldy RD; Center for Scientific Education and Leadership, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, 30333, United States of America., Bernstein KT; Center for Scientific Education and Leadership, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, 30333, United States of America., Galloway E; Division of STD Prevention, U.S Centers for Disease control and Prevention, Atlanta, Georgia 30333 United States of America., Learner ER; Division of STD Prevention, U.S Centers for Disease control and Prevention, Atlanta, Georgia 30333 United States of America. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | The Journal of infectious diseases [J Infect Dis] 2024 Jul 31. Date of Electronic Publication: 2024 Jul 31. |
| DOI: | 10.1093/infdis/jiae383 |
| Abstrakt: | Introduction: There is no licensed vaccine against gonorrhea but Neisseria meningitidis serogroup B outer membrane vesicle-based vaccines, like MenB-4C, may offer cross-protection against gonorrhea. This systematic review and meta-analysis synthesized the published literature on MenB-4C vaccine effectiveness against gonorrhea. Methods: We conducted a literature search of electronic databases (PubMed, Medline, Embase, Global Health, Scopus, Google Scholar, CINAHL, and Cochrane Library) to identify peer-reviewed papers, published in English, from 1/1/2013-7/12/2024 that reported MenB-4C vaccine effectiveness estimates against gonorrhea and gonorrhea/chlamydia co-infection, and the duration of MenB-4C vaccine-induced protection. We estimated pooled MenB-4C vaccine effectiveness (≥1 dose) against gonorrhea using the DerSimonian-Laird random effects model. Results: Eight papers met our eligibility criteria. Receipt of ≥1 dose of MenB-4C vaccine was 23%-47% effective against gonorrhea. Two doses of MenB-4C vaccine were 33-40% effective against gonorrhea and one dose of MenB-4C vaccine was 26% effective. MenB-4C vaccine effectiveness against gonorrhea/chlamydia co-infection was mixed with two studies reporting effectiveness estimates of 32% and 44%, and two other studies showing no protective effect. MenB-4C vaccine effectiveness against gonorrhea was comparable in people living with HIV (44%) and people not living with HIV (23%-47%). Pooled MenB-4C vaccine effectiveness (≥1 dose) against gonorrhea was 32.4%. One study concluded that MenB-4C vaccine effectiveness against gonorrhea may wane approximately 36 months post-vaccination. Conclusion: MenB-4C vaccine is moderately effective against gonorrhea in various populations. Prospective clinical trials that assess the efficacy of MenB-4C against gonorrhea, gonorrhea/chlamydia co-infection, and duration of protection are warranted to strengthen this evidence. (Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|